# Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery

> **NCT00801411** · PHASE2 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 318 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00801411
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 318 (ESTIMATED)
- **Last updated:** 2009-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801411, "Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00801411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*